A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT ID: NCT06577025

This clinical trial is studying new treatment combinations for patients with a type of cancer called multiple myeloma, specifically those who have just been diagnosed and are considered standard-ri...

Recruiting

Phase: PHASE2 Type: interventional Locations: New York, New York, United States, Duarte, California, United States +14 more

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT ID: NCT05552222

This clinical trial is studying two combinations of medications for patients with newly diagnosed multiple myeloma, a type of blood cancer. The combinations being tested are teclistamab with daratu...

Recruiting

Phase: PHASE3 Type: interventional Locations: Durham, North Carolina, United States, Durham, North Carolina, United States +338 more

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT ID: NCT06550895

This clinical trial is studying two treatments, Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab, for patients with high-risk multiple myeloma, a type of blood cancer. The goal is to evaluate ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Philadelphia, Pennsylvania, United States, Milwaukee, Wisconsin, United States +12 more

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

NCT ID: NCT06768489

This clinical trial is investigating a new treatment called JNJ-79635322, which is being tested either alone or in combination with two existing drugs, daratumumab or pomalidomide, for patients wit...

Recruiting

Phase: PHASE1 Type: interventional Locations: Ramat Gan, , Israel, Amsterdam, , Netherlands +13 more

Mosaic Trial for Stem Cell Transplant Recipients

NCT ID: NCT06960993

The Mosaic Trial is a research study designed to see if a special website can help adults with blood cancer who are getting stem cell transplants. The study will compare the experiences of patients...

Recruiting

Phase: NA Type: interventional Locations: Chicago, Illinois, United States, Washington, District Of Columbia, United States +1 more

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT ID: NCT04133636

This clinical trial is studying a new treatment called JNJ-68284528, which is a type of therapy that uses modified immune cells to fight multiple myeloma, a type of blood cancer. The main goal of t...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, New York, New York, United States +68 more

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

NCT ID: NCT06580223

This clinical trial is investigating whether aspirin or rivaroxaban, a type of blood thinner, can help prevent blood clots in patients with multiple myeloma, a type of cancer that affects the blood...

Not yet recruiting

Phase: PHASE3 Type: interventional Locations: Wuhan, Hu Bei, China

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT ID: NCT05201781

This clinical trial is looking at the long-term effects of a treatment called ciltacabtagene autoleucel (often referred to as cilta-cel) in patients who have been previously treated for multiple my...

Recruiting

Phase: PHASE4 Type: interventional Locations: Chicago, Illinois, United States, Boston, Massachusetts, United States +56 more

A Study of Daratumumab

NCT ID: NCT05438043

This clinical trial is studying a treatment called daratumumab for patients with multiple myeloma, a type of blood cancer, or smoldering multiple myeloma, which is a less aggressive form of the dis...

Recruiting

Phase: PHASE3 Type: interventional Locations: New York, New York, United States, Pessac, , France +88 more

National Cancer Institute "Cancer Moonshot Biobank"

NCT ID: NCT04314401

The "Cancer Moonshot Biobank" is a clinical trial that aims to gather blood and tissue samples from patients diagnosed with various types of cancer, including advanced stages of breast cancer, lung...

Recruiting

Type: observational Locations: Des Moines, Iowa, United States, Scarborough, Maine, United States +177 more

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT ID: NCT02693535

The TAPUR trial is studying how effective certain FDA-approved drugs are for patients with advanced cancers, such as lymphoma, multiple myeloma, and solid tumors, that have specific genetic changes...

Recruiting

Phase: PHASE2 Type: interventional Locations: Ann Arbor, Michigan, United States, Philadelphia, Pennsylvania, United States +188 more

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT ID: NCT06169215

This clinical trial is studying a new treatment approach for patients with high-risk newly diagnosed multiple myeloma, a type of blood cancer. Researchers are comparing a combination of four medica...

Recruiting

Phase: PHASE2 Type: interventional Locations: New Haven, Connecticut, United States, Orange, California, United States +26 more

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT ID: NCT06179888

This clinical trial is studying the effects of a medication called iberdomide in patients with multiple myeloma who have recently received a treatment called idecabtagene vicleucel, which is a type...

Recruiting

Phase: PHASE2 Type: interventional Locations: Saint Louis, Missouri, United States, Oklahoma City, Oklahoma, United States +70 more

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

NCT ID: NCT06523621

This clinical trial is investigating whether a medication called nivolumab can help patients with multiple myeloma improve their treatment response after receiving another therapy called idecabtage...

Recruiting

Phase: PHASE2 Type: interventional Locations: Charlotte, North Carolina, United States, Winston Salem, North Carolina, United States

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

NCT ID: NCT06876142

This clinical trial is looking at a new treatment for adults with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer that often comes back after treatment or doesn’t respond to ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Bethesda, Maryland, United States

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT ID: NCT06413498

This clinical trial, called iMMagine-3, is comparing a new treatment called anitocabtagene autoleucel to standard care for patients with multiple myeloma who have not responded to previous treatmen...

Recruiting

Phase: PHASE3 Type: interventional Locations: Ann Arbor, Michigan, United States, Boston, Massachusetts, United States +84 more

Collection of Tissue Samples for Cancer Research

NCT ID: NCT00900198

This clinical trial is focused on collecting tissue samples from patients with different types of cancer, including neoplasms, lymphomas, multiple myeloma, and myelodysplastic syndrome. The goal is...

Recruiting

Type: observational Locations: Baltimore, Maryland, United States, Columbus, Ohio, United States +17 more

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT ID: NCT05583617

This clinical trial, titled "A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma," is testing various treatment combinations for people diagnosed...

Recruiting

Phase: PHASE1 Type: interventional Locations: Valencia, , Spain, Badalona, , Spain +27 more

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT ID: NCT06103838

This clinical trial is studying a new imaging method using a substance called 18F-fluciclovine to see if it can better detect multiple myeloma (MM), a type of blood cancer, compared to the current ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT ID: NCT05497804

The REACH Trial is a clinical study exploring the effectiveness of a combination of chemotherapy drugs to treat high-risk multiple myeloma, which is a type of blood cancer. This trial specifically ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Scottsdale, Arizona, United States, Rochester, Minnesota, United States +1 more

Main Menu

Clinical Trials for Multiple Myeloma

425 Active Trials Found

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Mosaic Trial for Stem Cell Transplant Recipients

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

A Study of Daratumumab

National Cancer Institute "Cancer Moonshot Biobank"

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Collection of Tissue Samples for Cancer Research

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

18F-Fluciclovine PET/CT in Multiple Myeloma

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Related Conditions